Newscasting from ACC 2024: SHASTA-2 and Plozasiran in Severe Hypertriglyceridemia, with Christie Ballantyne, MD
New data from the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions offers the cardiology community the latest insights into the effects of plozasiran in patients with severe hypertriglyceridemia.
Results of the phase 2b SHASTA-2 trial, which assessed use of the investigational APOC3-targeted small interfering–RNA (siRNA) therapeutic in patients with fasting triglyceride levels of 500 mg/dL or greater, indicate use was associated with least squares (LS)–mean reductions in triglyceride levels of −57% at 24 weeks, with the significant treatment difference persisting at 48 weeks. Investigators noted these were driven by a placebo-adjusted reduction in APOC3 and more than 90% of patients achieved a fasting triglyceride level less than 500 mg/dL.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
